Author

S. Pohlmann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Organism:mouse· 3 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1 Organism:multiple species· 1 Assay:proteomics· 1

Frequent Co-Authors

M. Hoffmann· 3 shared A. D. Werts· 1 shared A. Ensser· 1 shared A. Klippert· 1 shared A. Kratzel· 1 shared A. M. Healy· 1 shared A. R. Charbit· 1 shared A. S. Peter· 1 shared

Activity by Year

2018-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

M. Hoffmann

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Macrophage- and CD4+ T cell-derived SIV differ in glycosylation, infectivity and neutralization sensitivity

C. B. Karsten, F. F. R. Buttner, S. Cajic, I. Nehlmeier, B. Roshani, A. Klippert, U. Sauermann, N. Stolte-Leeb, U. Reichl, R. Gerardy-Schahn, E. Rapp, C. Stahl-Hennig, S. Pohlmann

This study compares glycosylation, infectivity, and neutralization sensitivity of SIV produced in macrophages versus CD4+ T cells, revealing differences in glycan profiles and their impact on viral spread and antibody neutralization.

bioRxiv · Jan 2, 2024Microbiology

A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model

A. S. Peter, E. Roth, S. R. Schulz, K. Fraedrich, T. Steinmetz, D. Damm, M. Hauke, E. Richel, S. Mueller-Schmucker, K. Habenicht, V. Eberlein, L. Issmail, N. Uhlig, S. Dolles, E. Gruner, , H.-M. Jack

The paper identifies two clusters of non-competing neutralizing antibodies against SARS-CoV-2 that protect mice from infection and weight loss.

bioRxiv · Apr 16, 2021 · PreprintImmunology

Thiol drugs decrease SARS-CoV-2 lung injury in vivo and disrupt SARS-CoV-2 spike complex binding to ACE-2 in vitro

K. Khanna, W. Raymond, J. Jin, A. R. Charbit, I. Gitlin, M. Tang, A. D. Werts, E. G. Barrett, J. M. Cox, S. M. Birch, R. Martinelli, H. S. Sperber, S. Franz, S. Pillai, A. M. Healy, , J. V. Fahy

Thiol drugs inhibit SARS-CoV-2 infection in vitro and reduce lung injury in vivo, supporting their potential as COVID-19 treatments.

bioRxiv · Dec 8, 2020 · PreprintMicrobiology

LY6E impairs coronavirus fusion and confers immune control of viral disease

S. Pfaender, K. B. Mar, E. Michailidis, A. Kratzel, D. Hirt, P. V'kovski, W. Fan, N. Ebert, H. Stalder, H. Kleine-Weber, M. Hoffmann, H. H. Hoffmann, M. Saeed, R. Dijkman, E. Steinmann, , V. Thiel

This study identifies LY6E as an interferon-induced gene that restricts coronavirus entry and pathogenesis by inhibiting spike protein-mediated fusion and protecting immune cells.

Nature Microbiology · Jul 23, 2020Peer-reviewedMicrobiology

Development and use of Lentiviral Vectors Pseudotyped with Influenza B Haemagglutinins: application to vaccine immunogenicity, mAb potency and sero-surveillance studies

F. Ferrara, G. Carnell, R. Kinsley, E. Bottcher-Friebertshauser, S. Pohlmann, S. Scott, S. Fereidouni, D. Corti, P. Kellam, S. Gilbert, N. J. Temperton

The paper develops influenza B haemagglutinin-pseudotyped lentiviral vectors as sensitive tools for detecting neutralizing and cross-reactive antibodies in vaccine and sero-surveillance studies.

bioRxiv · Dec 10, 2018 · PreprintMicrobiology